AXIM Biotechnologies, Inc.
AXIM
$0.01
$0.0019.05%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.50K | 53.00K | 12.90K | 9.60K | 9.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.50K | 53.00K | 12.90K | 9.60K | 9.90K |
| Cost of Revenue | 1.70K | -- | -- | -- | -- |
| Gross Profit | 15.70K | 53.00K | 12.90K | 9.60K | 9.90K |
| SG&A Expenses | 473.00K | 333.80K | 623.70K | 456.60K | 566.80K |
| Depreciation & Amortization | 108.10K | 108.00K | 106.80K | 106.80K | 106.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 586.90K | 457.30K | 766.80K | 598.10K | 707.70K |
| Operating Income | -569.40K | -404.40K | -753.90K | -588.50K | -697.70K |
| Income Before Tax | -2.27M | -292.30K | -1.90M | 328.50K | -3.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.27M | -292.30K | -1.90M | 328.50K | -3.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.27M | -292.30K | -1.90M | 328.50K | -3.72M |
| EBIT | -569.40K | -404.40K | -753.90K | -588.50K | -697.70K |
| EBITDA | -461.30K | -296.40K | -647.20K | -481.80K | -591.00K |
| EPS Basic | -0.01 | 0.00 | -0.01 | 0.00 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | 0.00 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 288.91M | 261.40M | 238.47M | 232.36M | 226.26M |
| Average Diluted Shares Outstanding | 288.91M | 261.40M | 238.47M | 478.51M | 226.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |